E C de Heer
Overview
Explore the profile of E C de Heer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Heer E, Zois C, Bridges E, van der Vegt B, Sheldon H, Veldman W, et al.
J Exp Clin Cancer Res
. 2023 Aug;
42(1):220.
PMID: 37635223
No abstract available.
2.
de Heer E, Zois C, Bridges E, van der Vegt B, Sheldon H, Veldman W, et al.
J Exp Clin Cancer Res
. 2023 Jun;
42(1):143.
PMID: 37280675
Background: Hypoxia-induced glycogen turnover is implicated in cancer proliferation and therapy resistance. Triple-negative breast cancers (TNBCs), characterized by a hypoxic tumor microenvironment, respond poorly to therapy. We studied the expression...
3.
Bisschop C, de Heer E, Brouwers A, Hospers G, Jalving M
Crit Rev Oncol Hematol
. 2020 Jul;
153:103044.
PMID: 32673997
F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) is increasingly used in patients with advanced melanoma. Immune checkpoint inhibitors and BRAF/MEK-targeted therapy have transformed the therapeutic landscape of metastatic melanoma. Consequently,...
4.
de Heer E, Hulshoff J, Klerk D, Burgerhof J, de Groot D, Plukker J, et al.
Ann Surg Oncol
. 2017 Feb;
24(7):1811-1820.
PMID: 28188501
Background: Patients with curable esophageal cancer (EC) who proceed beyond the original Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) eligibility criteria are also treated with neoadjuvant chemoradiotherapy (nCRT)....